Chris Mix

Chris Mix is a highly experienced professional in the pharmaceutical and biotechnology industry. Chris has held various leadership positions throughout their career. Chris began their most recent role in 2020 at Dyne Therapeutics, where they served as the Senior Vice President of Clinical Development. During their time at Dyne, they contributed to the development of therapies targeting muscle diseases such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. Prior to joining Dyne, Chris worked as a Clinical Development Consultant at a self-employed capacity in 2019 and as the Vice President of Rare Genetic Disease at Agios Pharmaceuticals from 2018 to 2019. Chris also held the position of Vice President of Clinical Development at Sarepta Therapeutics from 2017 to 2018, where they oversaw various clinical operations and functions focused on Duchenne muscular dystrophy. Furthermore, Chris has held significant positions at prominent companies such as Alexion Pharmaceuticals, where they served as an Executive Director of Global Medical Sciences from 2015 to 2017, and Amgen, where they were the Executive Medical Director of Global Development from 2003 to 2015. Chris also has experience in research and teaching through positions held at Tufts Medical Center, Beth Israel Deaconess Medical Center, and Harvard Medical School. With their extensive background, Chris Mix brings a wealth of knowledge and expertise to the field of pharmaceutical and biotechnology.

Chris Mix attended Haverford College from 1985 to 1989, where they obtained a Bachelor's Degree in Chemistry. Chris then pursued further education at UMass Chan Medical School from 1990 to 1995, earning a Doctor of Medicine (MD) degree. In 2001, they attended Tufts University, completing a Master of Science (MS) program in Clinical Care Research from 2001 to 2003. It is not specified when they attended The Rivers School, and the degree obtained is also not provided.